Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESORT: Rituximab Dosing Strategies in Low Tumor Burden Indolent NHL
NCT00075946Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jan 2004
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Eastern Cooperative Oncology Group. Started Jan 2004; status: completed.
02
Drugs
rituximab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00075946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075946.